Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial

Name: Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial
Creator: Linda Stein Gold
Published: 2024-03-15T14:24:40.488Z
Keywords: Medicine, Dermatology, Psoriasis

Stein Gold, Linda; Adam, David; Albrecht, Lorne; Alonso-Llamazares, Javier; Ferris, Laura; Gooderham, Melinda; Hong, Chih-ho; Kempers, Steven; Kircik, Leon; Lebwohl, Mark; Loo, Wei Jing; Nahm, Walter; Papp, Kim; Stewart, Daniel; Toth, Darryl; Zirwas, Matthew; Krupa, David; Snyder, Scott; Burnett, Patrick; Higham, Robert; Berk, David

doi:10.17632/zwjz7w95mh.1

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial

Published: 15 March 2024| Version 1 | DOI: 10.17632/zwjz7w95mh.1

Contributors:

Linda Stein Gold, David Adam, Lorne Albrecht, Javier Alonso-Llamazares, Laura Ferris, Melinda Gooderham, Chih-ho Hong, Steven Kempers, Leon Kircik, Mark Lebwohl, Wei Jing Loo, Walter Nahm, Kim Papp, Daniel Stewart, Darryl Toth, Matthew Zirwas, David Krupa, Scott Snyder, Patrick Burnett, Robert Higham, David Berk

Description

Supplementary data to support the primary manuscript "Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial"

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial

Description

Files

Categories

Licence